EGFR kinase domain mutations - functional impact and relevance for lung cancer therapy (Q36758325)

16 August 2017

1 reference

title

EGFR kinase domain mutations - functional impact and relevance for lung cancer therapy (English)

1 reference

16 August 2017

1 reference

D Irmer

1

1 reference

16 August 2017

J O Funk

series ordinal

2

1 reference

16 August 2017

A Blaukat

series ordinal

3

1 reference

16 August 2017

language of work or name

English

0 references

publication date

12 March 2007

1 reference

16 August 2017

1 reference

16 August 2017

volume

26

1 reference

16 August 2017

issue

39

1 reference

16 August 2017

page(s)

5693-5701

1 reference

Enhancement of sensitivity to tumor necrosis factor alpha in non-small cell lung cancer cells with acquired resistance to gefitinib

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210383

7 January 2021

Small in-frame deletion in the epidermal growth factor receptor as a target for ZD6474.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210383

7 January 2021

A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210383

7 January 2021

Somatic mutations of EGFR in colorectal cancers and glioblastomas

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210383

7 January 2021

Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210383

7 January 2021

Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210383

7 January 2021

Mutation of threonine 766 in the epidermal growth factor receptor reveals a hotspot for resistance formation against selective tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210383

7 January 2021

Ethnic differences in response to epidermal growth factor receptor tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210383

7 January 2021

Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210383

7 January 2021

Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210383

7 January 2021

Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210383

7 January 2021

Distinctive activation patterns in constitutively active and gefitinib-sensitive EGFR mutants

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210383

7 January 2021

Gefitinib response of erlotinib-refractory lung cancer involving meninges--role of EGFR mutation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210383

7 January 2021

Baseline gene expression predicts sensitivity to gefitinib in non-small cell lung cancer cell lines.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210383

7 January 2021

Epidermal growth factor receptor mutation type III transfected into a small cell lung cancer cell line is predominantly localized at the cell surface and enhances the malignant phenotype

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210383

7 January 2021

Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210383

7 January 2021

ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210383

7 January 2021

Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210383

7 January 2021

A small molecule-kinase interaction map for clinical kinase inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210383

7 January 2021

Lung cancer * 9: Molecular biology of lung cancer: clinical implications

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210383

7 January 2021

High expression of ErbB family members and their ligands in lung adenocarcinomas that are sensitive to inhibition of epidermal growth factor receptor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210383

7 January 2021

Mutations and addiction to EGFR: the Achilles 'heal' of lung cancers?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210383

7 January 2021

Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210383

7 January 2021

Acquired gefitinib-resistant mutation of EGFR in a chemonaive lung adenocarcinoma harboring gefitinib-sensitive mutation L858R

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210383

7 January 2021

Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210383

7 January 2021

Epidermal growth factor receptor inhibition strategies in oncology

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210383

7 January 2021

Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210383

7 January 2021

Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210383

7 January 2021

Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210383

7 January 2021

Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210383

7 January 2021

Enhanced cytotoxicity induced by gefitinib and specific inhibitors of the Ras or phosphatidyl inositol-3 kinase pathways in non-small cell lung cancer cells.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210383

7 January 2021

Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210383

7 January 2021

The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210383

7 January 2021

Epidermal growth factor-independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210383

7 January 2021

Selecting patients for epidermal growth factor receptor inhibitor treatment: A FISH story or a tale of mutations?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210383

7 January 2021

A quantitative protein interaction network for the ErbB receptors using protein microarrays

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210383

7 January 2021

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210383

7 January 2021

An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210383

7 January 2021

Reduction of PTEN protein and loss of epidermal growth factor receptor gene mutation in lung cancer with natural resistance to gefitinib (IRESSA).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210383

7 January 2021

Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210383

7 January 2021

Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210383

7 January 2021

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210383

7 January 2021

Assessing EGFR mutations

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210383

7 January 2021

Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210383

7 January 2021

Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210383

7 January 2021

Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210383

7 January 2021

First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer: a phase II study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210383

7 January 2021

Protein kinase inhibitors: insights into drug design from structure.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210383

7 January 2021

The ErbB receptors and their ligands in cancer: an overview.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210383

7 January 2021

Expression of constitutively activated EGFRvIII in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210383

7 January 2021

Molecular biology of epidermal growth factor receptor inhibition for cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210383

7 January 2021

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210383

7 January 2021

Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210383

7 January 2021

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210383

7 January 2021

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210383

7 January 2021

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210383

7 January 2021

SH2 domains, interaction modules and cellular wiring

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210383

7 January 2021

The type III epidermal growth factor receptor mutation. Biological significance and potential target for anti-cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210383

7 January 2021

Epidermal growth factor receptor (EGFR) antibody down-regulates mutant receptors and inhibits tumors expressing EGFR mutations

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210383

7 January 2021

Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210383

7 January 2021

EGFR amplification and lack of activating mutations in metaplastic breast carcinomas

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210383

7 January 2021

Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210383

7 January 2021

Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210383

7 January 2021

Unraveling the mystery of prognostic and predictive factors in epidermal growth factor receptor therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210383

7 January 2021

Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210383

7 January 2021

Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycins

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210383

7 January 2021

Epidermal growth factor receptor domain II, IV, and kinase domain mutations in human solid tumors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210383

7 January 2021

Autocrine, paracrine and juxtacrine signaling by EGFR ligands

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210383

7 January 2021

Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210383

7 January 2021

Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210383

7 January 2021

EGFR mutation and response of lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210383

7 January 2021

Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210383

7 January 2021

Erlotinib in lung cancer - molecular and clinical predictors of outcome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210383

7 January 2021

Responsiveness to cetuximab without mutations in EGFR.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210383

7 January 2021

ErbB-2 amplification inhibits down-regulation and induces constitutive activation of both ErbB-2 and epidermal growth factor receptors.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210383

7 January 2021

The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210383

7 January 2021

Identifiers

DOI

10.1038/SJ.ONC.1210383

1 reference

Dimensions Publication ID

16 August 2017

1050198010

0 references

1 reference